iBeam Technology Pursues IPO... Samsung Securities Selected as Lead Manager

[Asia Economy Reporter Lee Gwan-joo] Ibeam Technology, a company specializing in bio-microscopy, announced on the 23rd that it has selected Samsung Securities as the lead underwriter for its initial public offering (IPO).

A representative of Ibeam Technology stated, “We are beginning full-scale preparations aiming for a KOSDAQ technology-specialized listing,” adding, “Samsung Securities was chosen as the lead underwriter due to its expertise and know-how specialized in technology-specialized listings, having successfully led numerous bio-technology company listings.”

Founded in 2017, Ibeam Technology has developed technology capable of real-time tracking and monitoring of cellular changes inside living organisms, which was previously impossible with existing MRI or CT technologies. The company successfully commercialized 'In Vivo Microscopy Cell Imaging (IVM)', which allows direct observation of cells within living internal organs.

Kim Pil-han, CEO of Ibeam Technology, said, “Based on the resources secured through a successful IPO, Ibeam Technology will leap forward as a leading company in the global bio-health market with its bio-microscopy solution platform,” and added, “We also plan to actively expand globally into advanced AI medical devices usable during cancer surgeries.”

Ibeam Technology began with Series A funding and completed Series C funding last month, securing a total cumulative investment of 26 billion KRW to date.

This content was produced with the assistance of AI translation services.